Navigation Links
Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Date:11/18/2011

ts in EYLEA.

The recommended dose for EYLEA is 2 mg administered by intravitreal injection every four weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg once every eight weeks (2 months).  Although EYLEA may be dosed as frequently as 2 mg every four weeks (monthly), additional efficacy was not demonstrated when EYLEA was dosed every four weeks compared to every eight weeks.

There is a potential risk of arterial thromboembolic events (ATEs) following use of intravitreal VEGF inhibitors, including EYLEA, defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).  The incidence of ATEs with EYLEA in clinical trials was low (1.8%).

Serious adverse reactions related to the injection procedure have occurred in less than 0.1% of intravitreal injections with EYLEA and include endophthalmitis, traumatic cataract, and increased intraocular pressure.

About the VIEW 1 and VIEW 2 Clinical StudiesThe safety and efficacy of EYLEA were assessed in two randomized, multi-center, double-masked, active-controlled studies in patients with wet AMD.  A total of 2412 patients were treated and evaluable for efficacy (1817 with EYLEA) in the two studies (VIEW 1 and VIEW 2). In each study, patients were randomly assigned in a 1:1:1:1 ratio to one of four dosing regimens: 1) EYLEA administered 2 mg every eight weeks following three initial monthly doses (EYLEA 2Q8); 2) EYLEA administered 2 mg every four weeks (EYLEA 2Q4); 3) EYLEA 0.5 mg administered every four weeks (EYLEA 0.5Q4); and 4) ranibizumab administered 0.5 mg every four weeks (ranibizumab 0.5Q4).  Patient ages ranged from 49 to 99 years with a mean of 76 years.

In both studies, the primary efficacy endpoint was the proportion of patients who maintained vision, defined as losing fewer than 15 letters of visual acuity at week 52 compared to baseline.  Data are available through week 52.
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
2. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
3. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
4. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
5. Regeneron Reports Second Quarter 2011 Financial and Operating Results
6. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
7. Trading in Regeneron Common Stock Halted
8. Regeneron Reports First Quarter 2011 Financial and Operating Results
9. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
10. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
11. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 Imprimis Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of proprietary compounded drug therapies, today ... financial results on Wednesday, May 13, 2015.  The company ... (1:30 p.m. PDT) on the same day to discuss ... The conference call and webcast will be open to ...
(Date:5/4/2015)... 4, 2015 EspeRare today announced ... Orphan Drug Designation (ODD) for rimeporide, its lead compound ... is a rare, life-threatening disease affecting boys early in ... is the most common and serious form of paediatric ... exchanger type-1 inhibitor, originally developed by Merck Serono in ...
(Date:5/1/2015)... CHAPEL HILL, N.C. , May 1, 2015 /PRNewswire/ ... from payers for its high price but manufacturer Gilead ... programs, strategic worldwide pricing, and effective public relations campaigns. ... and promise of less severe side effects propelled the ... quarter of 2014, the therapy,s first quarter on the ...
Breaking Medicine Technology:Imprimis Pharmaceuticals to Host its First Quarter 2015 Financial Report Conference Call and Webcast on May 13, 2015 at 4:30 p.m. EDT 2Imprimis Pharmaceuticals to Host its First Quarter 2015 Financial Report Conference Call and Webcast on May 13, 2015 at 4:30 p.m. EDT 3EspeRare's Investigational Compound Rimeporide Receives European Orphan Drug Designation in Duchenne Muscular Dystrophy 2New Study Examines Success Lessons of Sovaldi's and Harvoni's Blockbuster Launches 2
... Inc. (Nasdaq: STXS ) announced today financial results ... line with the preliminary results reported on October 13, 2010. ... margins, and reductions in both operating loss and net loss. ... million, compared to $13.3 million in the third quarter 2009. ...
... 2010 Cambrex Corporation (NYSE: CBM ) ... released on Wednesday, November 3, 2010 after the market ... conference call to discuss the third quarter 2010 financial ... November 4, 2010 at 8:30 a.m. Eastern Time Dial-in: ...
Cached Medicine Technology:Stereotaxis Reports Third Quarter Financial Results 2Stereotaxis Reports Third Quarter Financial Results 3Stereotaxis Reports Third Quarter Financial Results 4Stereotaxis Reports Third Quarter Financial Results 5Stereotaxis Reports Third Quarter Financial Results 6Stereotaxis Reports Third Quarter Financial Results 7
(Date:5/4/2015)... In response to the proposed mammography ... (USPSTF), Strategic Radiology® (SR®) fully aligns itself with ... Gynecologists (ACOG), the American College Of Surgeons, Susan ... (ACS), American College of Radiology (ACR), and Society ... screening mammography for women beginning at age 40 ...
(Date:5/4/2015)... For partners who’d like to become parents, Astroglide ... TTC™ (Trying to Conceive) . Unlike traditional lubricants that ... TTC™ is specially formulated to provide a better environment ... Disease Control, an average of one in eight ... pregnancy, and over 7.4 million women have ...
(Date:5/4/2015)... 04, 2015 Fast on the heels ... Trace Amounts, and Allison Folmar, JD, join over 150 ... internationally. , On Sunday, May 24, the conference presents ... possible?" Are you interested in Ryan Hinds' recovery story? ... our war against autism was written by Marcia ...
(Date:5/4/2015)... 2015 “St. Louis has long represented ... the West,” so it is the perfect place for ... Dr. Ben Litalien, Chief Development Officer for Zerorez. ... and will provide veterans with a $10,000 discount on ... to have a number of Military Veterans in its ...
(Date:5/3/2015)... 03, 2015 AvePoint, ... platforms and devices, today announced it is a ... Professionals (IAPP) Asia Privacy Forum, taking place May ... the event, AvePoint will showcase its compliance, risk, ... platforms. , Visit AvePoint for New Solutions ...
Breaking Medicine News(10 mins):Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 2Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 3Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 4Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 5Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 2Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 3Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 4
... hernias are one of the most common conditions treated ... annually. Although ventral hernia repair (VHR) is a common ... infection has been identified as a consistent risk factor ... which appears in the November issue of The ...
... such as Viagra use is linked to development of vision ... disorders have used Viagra medicines. It is found that it ... cause risk of blindness. Men most at risk for the ... heart disease, high blood pressure and high cholesterol, among other ...
... Findings presented at the American Society of Therapeutic Radiation ... antigen (PSA) // significantly reduces the mortality associated with ... most prevalent type of cancer found in men after ... in the male reproductive system, which produces some of ...
... is essential for the lipid and carbohydrate metabolism, and ... to insulin.// The use of glucose by the peripheral ... has potential impact on long-term complications. ,In ... and an association between the proper metabolic control and ...
... and colleagues have identified a candidate gene, Sipa1, ... in cancer. Cancer mortality is most often the ... studies from Kent Hunter’s group demonstrated that the ... efficiency. They expressed the polyoma middle-T transgene in ...
... in women after menopause has been found to enhance ... cholesterol (the “good” cholesterol) in women, according to a ... and is characterized by decreased levels of the female ... the vagina and uterus. In addition the hormone ...
Cached Medicine News:Health News:Predictors Of Wound Infection In Ventral Hernia Repair 2Health News:Impotence drug such as Viagra may cause Vision Loss 2Health News:Carnitine deficiency in children and adolescents with type 1 diabetes 2Health News:Researchers Identify Sipa 1 Gene, Responsible For Cancer Metastasis 2Health News:Testosterone Therapy can improve sexual function in postmenopausal women 2
Gentamicin is a selection antibiotic used for selection of a Bac-to-Bac recombinant expression bacmid following transposition. Gentamicin is provided as a solution at a concentration of 50 mg/ml....
1.0% Tryptone, 0.5% yeast extract, 0.5% Sodium Chloride, 1.5% agarose....
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride, 1.5% agar....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Medicine Products: